Genomictree

Genomictree EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Genomictree (228760.KQ) as of Nov 4, 2026 is -41.83. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -27.63 — a change of 51.40% (lower).

EV/FCF

-41.83

YoY

51.40%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Genomictree is 2025 -41.83 . EV/FCF (Enterprise Value to Free Cash Flow) of Genomictree was 2024 -27.63 . It decreases by 51.40% lower compared to the previous year.

The Genomictree EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-113.56 KRW
Jan 1, 2019
-49.26 KRW
Jan 1, 2020
-42.94 KRW
Jan 1, 2021
-29.79 KRW
Jan 1, 2022
185.14 KRW
Jan 1, 2023
-40.90 KRW
Jan 1, 2024
-27.63 KRW
Jan 1, 2025
-41.83 KRW
The Genomictree EV/FCF history
YEAREV/FCFYoY
-41.83+51.40%
-27.63-32.46%
-40.90-122.09%
185.14-721.55%
-29.79-30.64%
-42.94-12.83%
-49.26-56.62%
-113.56-46.12%
-210.78-65.12%
-604.25+12.53%
-536.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomictree Stock analysis

What does Genomictree do? Genomictree, Inc. generates revenue by developing and supplying diagnostic products focused on cancer screening and prognosis. The firm conducts genomic analysis using microarrays and next generation sequencing analysis, while also performing clinical trials for its molecular diagnostic products. These offerings are designed to support medical professionals in identifying and managing various oncological conditions through advanced genetic testing methodologies. The company’s product portfolio is divided into cancer molecular diagnostic products and molecular genetic diagnostic products. The cancer molecular diagnostic segment includes specific tests for colorectal cancer, bladder cancer, lung cancer, stomach cancer, and cervical cancer. This targeted approach allows the firm to address a broad spectrum of oncological needs within the diagnostic market. Within the molecular genetic diagnostic products category, Genomictree, Inc. provides epidermal growth factor receptor (EGFR) mutation diagnosis and human papilloma virus (HPV) diagnostic products. By offering these specialized genetic tests, the company serves the healthcare sector with tools necessary for precise patient diagnosis and treatment planning based on genomic data. Genomictree is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomictree stock

EV/FCF (Enterprise Value to Free Cash Flow) of Genomictree is -41.83 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Genomictree changed from -27.63 to -41.83, representing a 51.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Genomictree since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Genomictree with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genomictree

All Key Metrics — Genomictree